AOA Dx Analysis: $17M Raised
What is AOA Dx?
AOA Dx is a women’s health diagnostics company founded in 2020 to develop early cancer detection tools. Its platform combines AI and multi-omics biomarkers, including lipidomics, to detect cancer earlier, with an initial emphasis on ovarian cancer. The company has also opened lab facilities in Denver and publishes research supporting its test development.
Location
6860 Broadway, Denver, Colorado 80221, United States
Employees
11-50
Founded
2020
Revenue
$5.7M
Product Features & Capabilities
- GlycoLocate™: multi-omics platform for early cancer detection, AKRIVIS GD™: blood test for early-stage ovarian cancer detection
How much AOA Dx raised
1 - $17 million
October 12, 2023Lead Investor: Good Growth Capital, RH, and others
Who are the founders of AOA Dx
OP
Oriana Papin-Zoghbi
CEO & Co-Founder
AF
Alex Fisher
COO & Co-Founder
AJ
Anna Jeter
Chief Business Officer & Co-Founder
Market Focus
AOA Dx primarily focuses on the healthcare industry, specifically in the area of early cancer detection through an AI-enabled platform that emphasizes women's health.
Competitors Overview
AOA Dx operates in the early cancer detection market, particularly focusing on women's health through AI-enabled platforms and multi-omics technology. Its main competitors include:
-
Genecker: This company offers ultra-precision cancer diagnosis services using advanced technologies like CRISPR/Cas9 for DNA analysis. Their focus is on selective analysis of wild-type and mutant DNA, which may provide a different approach to cancer detection compared to AOA Dx's multi-omics platform.
-
Amadix: A molecular diagnostics company specializing in liquid biopsy for early cancer detection. Amadix develops non-invasive blood tests aimed at colorectal, lung, and pancreatic cancers. Their focus on liquid biopsy technology contrasts with AOA Dx's emphasis on tumor marker gangliosides.
-
Aspira Women's Health: This company focuses on gynecologic diseases, particularly ovarian cancer, through AI-powered tests. Aspira's products are designed to help healthcare providers stratify risk and optimize treatment plans, which aligns closely with AOA Dx's mission but may differ in specific methodologies and target cancers.
-
GRAIL: Known for its multi-cancer early detection tests, GRAIL utilizes next-generation sequencing and machine learning to identify multiple cancer types from a single blood sample. Their broad approach to cancer detection may offer a more comprehensive screening option compared to AOA Dx's targeted focus.
-
Nevia Bio: This innovative company is developing AI-driven diagnostic solutions for early detection of gynecological cancers, particularly ovarian cancer, through analysis of vaginal fluid. Their unique approach to using vaginal secretions for cancer detection presents a notable difference from AOA Dx's methodologies.
These competitors highlight various technological approaches and focuses within the early cancer detection market, showcasing differences in methodologies, target cancers, and diagnostic technologies.
Business Model
Revenue from proprietary technology commercialization and funding for cancer detection innovations.
Investors
- Avestria Ventures
- AlleyCorp
- The Helm
- RH Capital
See something that needs updating? Suggest edits to this profile.